Stefan Luzi - Gilde Healthcare

team
Venture&Growth

All team members
Stefan Luzi
Partner Therapeutics
Venture&Growth
The Netherlands

Stefan Luzi

Partner - Therapeutics
Venture&Growth

Stefan Luzi joined Gilde Healthcare in 2015. He is focusing on venture and growth capital investments in the biopharmaceutical sector. He led several investments and currently represents Gilde on the boards of Lava Therapeutics B.V. and Amphista Therapeutics Ltd.

Prior to joining Gilde, Stefan worked at Merck KGaA where he completed international assignments in the Global Business Intelligence and M Ventures divisions. Additionally, he was involved in various consulting projects spanning the pharmaceutical and chemical departments at Merck and co-moderated Merck Serono’s innovation competitions.

Stefan received a B.Sc. in Biology and M.Sc. in Biotechnology from the Swiss Federal Institute of Technology Zurich (ETH) and his MPhil in Bioscience Enterprise from the University of Cambridge. He completed his Ph.D. with Nobel Laureate Sir Gregory Winter at the MRC Laboratory of Molecular Biology in Cambridge, where he developed a bicyclic peptide-based drug discovery platform.

He is a Swiss citizen based in Gilde’s Utrecht office.

Henry Zubaida

Investment Manager Healthtech
Venture&Growth
Henry Zubaida joined Gilde Healthcare in 2018 and focuses on the Healthtech sector. He has been involved in several investments including Big Health, Withings and Volta Medical. He is a board observer at FIRE1, Withings...

Gülbahar Gülten

Controller
Gülbahar Gülten joined Gilde Healthcare in 2022. Gulbahar is responsible for the financial administration, the preparation of reports and the management of the administrative organization of the various Gilde Healthcare entities. Before joining Gilde, Gulbahar...

Karthik Bolisetty

Senior Associate Healthtech
Venture&Growth
Karthik Bolisetty joined Gilde Healthcare in 2023 in the Boston office and focuses on Healthtech. Prior to joining Gilde, Karthik was on the investment team at Northpond Ventures, where he focused primarily on investments in...